{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"4.3","value":"1.7"},{"groupId":"OG001","lowerLimit":"2.6","upperLimit":"4.7","value":"4.1"},{"comment":"The 95% Confidence Interval upper limit was not estimable (i.e. below the level of detection).","groupId":"OG002","lowerLimit":"3.2","upperLimit":"NA","value":"4.6"},{"comment":"The 95% Confidence Interval upper limit was not estimable (i.e. below the level of detection).","groupId":"OG003","lowerLimit":"2.8","upperLimit":"NA","value":"5.5"},{"comment":"The 95% Confidence Interval upper limit was not estimable (i.e. below the level of detection).","groupId":"OG004","lowerLimit":"1.4","upperLimit":"NA","value":"1.5"},{"comment":"The 95% Confidence Interval upper limit was not estimable (i.e. below the level of detection).","groupId":"OG005","lowerLimit":"1.5","upperLimit":"NA","value":"2.7"},{"groupId":"OG006","lowerLimit":"1.3","upperLimit":"10","value":"1.5"},{"comment":"The 95% Confidence Interval upper limit was not estimable (i.e. below the level of detection).","groupId":"OG007","lowerLimit":"1.4","upperLimit":"NA","value":"2.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"11"}],"units":"Participants"}],"description":"Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression (PD) is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (PD: Any new lesion or increase by \\>= 50% of previously involved sites from nadir).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 3mg/kg nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Initial Single"},{"description":"Patients receive 3mg/kg nivolumab IV over 30 minutes and 1mg/kg ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive 3mg/kg nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Initial Dual"},{"description":"Dedifferentiated liposarcoma (LPS) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"LPS Single"},{"description":"Dedifferentiated liposarcoma (LPS) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes and 1mg/kg ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive 3mg/kg nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.","id":"OG003","title":"LPS Dual"},{"description":"Undifferentiated Pleomorphic Sarcoma \\& Malignant Fibrous Histiocytoma (UPS/MFH) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"UPS/MFH Single"},{"description":"Undifferentiated Pleomorphic Sarcoma \\& Malignant Fibrous Histiocytoma (UPS/MFH) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes and 1mg/kg ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive 3mg/kg nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.","id":"OG005","title":"UPS/MFH Dual"},{"description":"Gastrointestinal stromal tumor (GIST) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG006","title":"GIST Single"},{"description":"Gastrointestinal stromal tumor (GIST) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes and 1mg/kg ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive 3mg/kg nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.","id":"OG007","title":"GIST Dual"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from randomization to first of either disease progression or death from any cause, assessed up to 3 years","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}